In male SOD1G93A mice, intraperitoneal Rilmenidine significantly decreased survival, objectively defined by the onset of hind limb paralysis, compared with vehicle treatment. In a separate study in male SOD1G93A mice, Rilmenidine increased spinal cord LC3-II levels at symptom onset relative to vehicle treatment. In adult male diabetic Wistar rats, oral Rilmenidine produced a statistically significant reduction in plasma glucose compared with the diabetes + saline group. [2,3]
Rilmenidine and survival in mutant SOD1 mice
Animal study · male SOD1G93A mice; C57BL/6 background; n = 10 mice per group [2]
Male SOD1G93A mice received Rilmenidine by intraperitoneal injection. Survival, objectively defined by the onset of hind limb paralysis, was significantly decreased compared with vehicle-treated mice.
Conditions shared by the study groups
- Route
- intraperitoneal (i.p.) injections
- Treatment course
- Starting from postnatal day 60 (P60); 4-times a week
- Vehicle
- sterile DPBS
- Rilmenidine 10 mg/kg
- Model: male SOD1G93A mice; C57BL/6 background; n = 10 mice per group
Methods and source locations
Compound reported in the paper: Rilmenidine
Evidence for Rilmenidine as the phosphate form reported in the paper, not the free base/neutral form supplied as A10794; no salt equivalence, dose conversion or lot validation.
Results > Rilmenidine promotes disease progression and augments motor neuron degeneration while having no effect on glial pathology in mutant SOD1 mice (S70); Materials and Methods > Transgenic mice and rilmenidine treatment (S140, S141, S142); Figure 7. legend (S229)
survival objectively defined by the onset of hind limb paralysis: survival objectively defined by the onset of hind limb paralysis; comparator: vehicle-treated mice — Results > Rilmenidine promotes disease progression and augments motor neuron degeneration while having no effect on glial pathology in mutant SOD1 mice (S70)
Rilmenidine 10 mg/kg · Results > Rilmenidine promotes disease progression and augments motor neuron degeneration while having no effect on glial pathology in mutant SOD1 mice (S70); Materials and Methods > Transgenic mice and rilmenidine treatment (S141)
Rilmenidine reduces plasma glucose in diabetic rats
Animal study · male and adult Wistar rats; Diabetic rats; Group 3 (n = 10) [3]
Adult male diabetic Wistar rats received Rilmenidine at 0.2 mg/kg/day by oral gavage. Plasma glucose was 315.4 ± 9.1 mg/dL, a statistically significant reduction compared with the diabetes + saline group.
Conditions shared by the study groups
- Route
- oral gavage
- Treatment course
- for four weeks
- Rilmenidine 0.2 mg/kg/day
- Model: male and adult Wistar rats; Diabetic rats; Group 3 (n = 10)
- Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: Rilmenidine
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Methods > Settings > Animals (S2); Methods > Settings > Experimental protocol (S7, S11, S13); Results > Plasma glucose levels (S67, S69, S70)
plasma glucose levels: plasma glucose levels; comparator: diabetes + saline treatment group — Methods > Settings > Experimental protocol (S13); Results > Plasma glucose levels (S69, S70)
Rilmenidine 0.2 mg/kg/day · Methods > Settings > Experimental protocol (S13); Results > Plasma glucose levels (S69, S70)
Rilmenidine and spinal cord LC3-II levels
Animal study · male SOD1G93A mice; C57BL/6 background; n = 3-5 mice [2]
Male SOD1G93A mice received Rilmenidine by intraperitoneal injection. At symptom onset, spinal cord LC3-II levels were higher than in vehicle-treated mice.
Conditions shared by the study groups
- Route
- intraperitoneal (i.p.) injections
- Treatment course
- Starting from postnatal day 60 (P60); 4-times a week; collected at symptom onset (P90)
- Vehicle
- sterile DPBS
- Rilmenidine 10 mg/kg
- Model: male SOD1G93A mice; C57BL/6 background; n = 3-5 mice
Methods and source locations
Compound reported in the paper: Rilmenidine
Evidence for Rilmenidine as the phosphate form reported in the paper, not the free base/neutral form supplied as A10794; no salt equivalence, dose conversion or lot validation.
Results > Rilmenidine enhances MTOR-independent macroautophagy and mitophagy in spinal cords of mutant SOD1 mice (S49, S50); Materials and Methods > Transgenic mice and rilmenidine treatment (S140, S141, S142); Figure 5. legend (S217)
LC3-II levels: LC3-II levels; comparator: vehicle-treated mice — Results > Rilmenidine enhances MTOR-independent macroautophagy and mitophagy in spinal cords of mutant SOD1 mice (S50)
Rilmenidine 10 mg/kg · Results > Rilmenidine enhances MTOR-independent macroautophagy and mitophagy in spinal cords of mutant SOD1 mice (S49, S50); Materials and Methods > Transgenic mice and rilmenidine treatment (S141)